Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945736 | 0.96 | GNAI3 (0.45) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL26228559 | 0.86 | GNAI3 (0.44) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL25499375 | 0.86 | DPP4 (0.47) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL26404945 | 0.85 | MAPT (0.48) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL25654325 | 0.85 | GNAI3 (0.45) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL23695831 | 0.84 | FAAH (0.50) | ITGB3ITGA2BMEN1KMT2AEPHX2 | |
| SCHEMBL26038883 | 0.82 | DPP8 (0.38) | ITGB3ITGA2BEPHX2FAAH | |
| SCHEMBL25499377 | 0.82 | DPP4 (0.48) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL26408533 | 0.82 | GNAI3 (0.57) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL26040658 | 0.80 | DPP8 (0.36) | ITGB3ITGA2BMAPTEPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ITGB3 3396/4885ITGA2B 3218/4885GNAI3 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.